Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

[1]  M. Voso,et al.  Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Mishra,et al.  Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2013, American journal of hematology.

[3]  Y. Miyazaki,et al.  [Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[4]  L. Arenillas,et al.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.

[5]  U. Germing,et al.  Correlation between the low marrow blast cutpoint and WHO classification for myelodysplastic syndromes , 2013, European journal of haematology.

[6]  F. Naeim.  8 – Myelodysplastic Syndromes/Neoplasms—Overview , 2013 .

[7]  U. Germing,et al.  Prognostic scoring systems in MDS. , 2012, Leukemia research.

[8]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[9]  U. Germing,et al.  Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. , 2012, Leukemia research.

[10]  C. Pascutto,et al.  Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool , 2012, Haematologica.

[11]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Pfeilstöcker,et al.  Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. , 2012, Leukemia research.

[13]  A. Stamatoullas,et al.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). , 2010, Leukemia research.

[14]  M. Lübbert,et al.  Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Valent,et al.  Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  U. Germing,et al.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome , 2009, Haematologica.

[17]  M. Cazzola,et al.  Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  U. Germing,et al.  Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. , 2009, Leukemia research.

[19]  L. Arenillas,et al.  Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome , 2008 .

[20]  J. Issa,et al.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.

[21]  C. Pascutto,et al.  WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2008, Blood.

[22]  Rainer Haas,et al.  Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes , 2008, Annals of Hematology.

[23]  C. Fonatsch,et al.  Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Ganser,et al.  Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes , 2008, Leukemia.

[25]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[26]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  U. Germing,et al.  Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Newson.  Confidence Intervals for Rank Statistics: Somers’ D and Extensions , 2006 .

[29]  U. Germing,et al.  Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. , 2006, Haematologica.

[30]  C. Steidl,et al.  Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) , 2005, Leukemia.

[31]  U. Germing,et al.  No increase in age-specific incidence of myelodysplastic syndromes. , 2004, Haematologica.

[32]  E. Estey,et al.  Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). , 2003, Blood.

[33]  J. Klein,et al.  Survival Analysis: Techniques for Censored and Truncated Data , 1997 .

[34]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[35]  U. Germing,et al.  Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. , 1994, Leukemia.

[36]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[37]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[38]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[39]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[40]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[41]  G. Schwarz.  Estimating the Dimension of a Model , 1978 .